Recent Updates — MLAB

Mesa Laboratories approved a restructuring program eliminating approximately 40 positions, representing about 6% of its workforce, primarily within the Clinical Genomics division. The plan also includes exiting the Hamburg, Germany facility upon lease expiration in February 2027 and reducing the San Diego footprint. Management estimates pre-tax charges of $2.6 million to $3.4 million, with cash expenditures of $2.9 million to $3.7 million expected over the next 12 months. The company aims to reduce annualized operating costs by approximately $9.3 million and reinvest $4.3 million into growth areas like Calibration Solutions and Asia commercial resources, resulting in a net annualized cost reduction of roughly $5.0 million. Mesa Laboratories designs and manufactures quality control solutions and life sciences tools for regulated industries.

Mesa Laboratories reported first-quarter fiscal 2027 results for the period ended June 30, 2026. Total revenues increased 1.0% to $60.1 million, with non-GAAP adjusted operating income rising 19.5% to $15.4 million excluding unusual items. The company repaid $8.7 million in debt, reducing its total net leverage ratio to 1.85. Net income decreased 40.3% to $2.8 million due to nonoperating expenses and foreign currency gains in the prior year period. A legal settlement of $382,000 was recorded as an unusual item. The company operates in the life science tools and quality control solutions industry.

Mesa Laboratories, Inc. announced the appointment of Lyndsey Crennen as Chief Accounting Officer, effective June 11, 2026. Ms. Crennen, who has been with the company since 2018 and served as Corporate Controller since 2022, will receive an annual base salary of $325,000. Her compensation package includes a target annual cash bonus of 40% of her base salary and a target annual long-term incentive award of $300,000. Mesa Laboratories, Inc. is a life sciences company that designs and manufactures products for the medical and pharmaceutical industries.